Ixico (IXI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 7.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 20.30
  • 52 Week Low: 6.75
  • Currency: UK Pounds
  • Shares Issued: 48.35m
  • Volume: 48,149
  • Market Cap: £3.38m

Ixico selected to support Alzheimer's trial

By Josh White

Date: Monday 21 Sep 2020

LONDON (ShareCast) - (Sharecast News) - Data analytics company Ixico has been selected by the Global Alzheimer's Platform Foundation (GAP) to support its planned 'Bio-Hermes' trial.
The AIM-traded firm said it would apply its expertise to collect positron emission tomography (PET) brain scans in qualifying imaging centres participating in Bio-Hermes, and provide analysis of the scans.

It said the core purpose of Bio-Hermes was the development of a bio-sample database to investigate biomarkers on a head-to-head basis, in conjunction with medical history elements.

The trial would include 1,000 volunteers over the age of 60 screened for preclinical Alzheimer's disease, prodromal Alzheimer's disease, or mild dementia Alzheimer's disease.

Observational biomarker studies consistently suggested that amyloid deposition and tau deposition in neurofibrillary tangles in the brain could be the sentinel events in Alzheimer's disease pathology.

In the Bio-Hermes trial, Avid Pharmaceuticals' 'Amyvid' would be used as the radioactive diagnostic agent to estimate beta-amyloid neuritic plaque density.

Ixico said the contract did not have a significant impact on its expectations of performance for the year, but would contribute to its "already strong" year-end order book.

"We are delighted to be selected by GAP as their prime choice for the analysis of PET scans in the Bio-Hermes trial," said chief executive officer Giulio Cerroni.

"With a reinvigorated level of interest in Alzheimer's disease, we are excited about the prospects of long-term collaboration with our colleagues at GAP who share our own commitment to reducing the time, cost, and risk for Alzheimer's disease trials.

"The support provided by Ixico staff on Bio-Hermes is an important commercial development in enhancing Ixico's market position in neuroimaging for Alzheimer's disease clinical trials."

At 1236 BST, shares in Ixico were down 2.75% at 81.2p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Ixico Market Data

Currency UK Pounds
Share Price 7.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 20.30
52 Week Low 6.75
Volume 48,149
Shares Issued 48.35m
Market Cap £3.38m

Ixico Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
39.89% above the market average39.89% above the market average39.89% above the market average39.89% above the market average39.89% above the market average
76.47% above the sector average76.47% above the sector average76.47% above the sector average76.47% above the sector average76.47% above the sector average
Price Trend
91.19% below the market average91.19% below the market average91.19% below the market average91.19% below the market average91.19% below the market average
66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average
Income Not Available
Growth
87.55% below the market average87.55% below the market average87.55% below the market average87.55% below the market average87.55% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average

Ixico Dividends

No dividends found

Trades for 29-May-2024

Time Volume / Share Price
15:11 66 @ 6.75p
13:35 48,000 @ 6.76p
08:00 83 @ 7.17p

Ixico Key Personnel

CEO Giulio Cerroni

Top of Page